Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial).

Date publication

juillet 2021

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Pereira H, Bouattour M, Dioguardi Burgio M, Assenat E, Grégory J, Bronowicki JP, Chatellier G, Vilgrain V,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34243077

Résumé

The aim of this ancillary study of the SARAH trial is to compare health-related quality of life (HRQoL) in patients with locally advanced or inoperable hepatocellular carcinoma (HCC) treated with transarterial radioembolisation (TARE) or sorafenib.

Mots clés

Health-related quality of life, Hepatocellular carcinoma, Sorafenib, Transarterial radioembolisation

Référence

Eur J Cancer. 2021 Jul 6;154:46-56